|
|
|
|
LEADER |
07277nma a2202113 u 4500 |
001 |
EB001992661 |
003 |
EBX01000000000000001155563 |
005 |
00000000000000.0 |
007 |
cr||||||||||||||||||||| |
008 |
210512 ||| eng |
020 |
|
|
|a books978-3-03943-293-6
|
020 |
|
|
|a 9783039432929
|
020 |
|
|
|a 9783039432936
|
100 |
1 |
|
|a Luparello, Claudio
|
245 |
0 |
0 |
|a Role of Natural Bioactive Compounds in the Rise and Fall of Cancers
|h Elektronische Ressource
|b Volume 2
|
260 |
|
|
|a Basel, Switzerland
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2020
|
300 |
|
|
|a 1 electronic resource (318 p.)
|
653 |
|
|
|a radiotherapy
|
653 |
|
|
|a EGCG
|
653 |
|
|
|a systematic review
|
653 |
|
|
|a MMPs
|
653 |
|
|
|a EGFR signaling
|
653 |
|
|
|a oleacein
|
653 |
|
|
|a XIAP antagonists
|
653 |
|
|
|a targeted delivery system
|
653 |
|
|
|a AKT
|
653 |
|
|
|a fucoidan
|
653 |
|
|
|a PD-1 immune checkpoint inhibitor and cancer immunotherapy
|
653 |
|
|
|a cell-cycle arrest
|
653 |
|
|
|a phosphofructokinase
|
653 |
|
|
|a cell signaling
|
653 |
|
|
|a caspase-independent cell death
|
653 |
|
|
|a β-glucans
|
653 |
|
|
|a Xenopus laevis
|
653 |
|
|
|a oral cancer inhibition
|
653 |
|
|
|a JAK/STAT
|
653 |
|
|
|a natural bioactive compound
|
653 |
|
|
|a tumor maintenance
|
653 |
|
|
|a immunotherapy
|
653 |
|
|
|a nutrition
|
653 |
|
|
|a gallic acid
|
653 |
|
|
|a carrageenan
|
653 |
|
|
|a signaling pathways
|
653 |
|
|
|a neurofibromas
|
653 |
|
|
|a persistent organic pollutants
|
653 |
|
|
|a Piper eriopodon, alkenylphenols
|
653 |
|
|
|a schwannomas
|
653 |
|
|
|a reactive oxygen species
|
653 |
|
|
|a XIAP-BIR3 domain
|
653 |
|
|
|a colorectal cancer
|
653 |
|
|
|a olive leaf extract
|
653 |
|
|
|a oleuropein
|
653 |
|
|
|a Biology, life sciences / bicssc
|
653 |
|
|
|a marine sponge
|
653 |
|
|
|a anticancer activities
|
653 |
|
|
|a cancer
|
653 |
|
|
|a isobolography
|
653 |
|
|
|a anti-proliferative
|
653 |
|
|
|a oncogenic cascades
|
653 |
|
|
|a lung cancer
|
653 |
|
|
|a renin-angiotensin system
|
653 |
|
|
|a colon cancer
|
653 |
|
|
|a Seahorse analysis
|
653 |
|
|
|a p53
|
653 |
|
|
|a mechanism
|
653 |
|
|
|a epigallocatechin-3-gallate (EGCG)
|
653 |
|
|
|a TRAIL
|
653 |
|
|
|a molecular mechanisms
|
653 |
|
|
|a autophagy
|
653 |
|
|
|a natural polyphenols
|
653 |
|
|
|a daidzein
|
653 |
|
|
|a invasion
|
653 |
|
|
|a adipocyte inflammation
|
653 |
|
|
|a EGFR TKI
|
653 |
|
|
|a cell death
|
653 |
|
|
|a NSCLC
|
653 |
|
|
|a natural product
|
653 |
|
|
|a cancer metabolism
|
653 |
|
|
|a Research and information: general / bicssc
|
653 |
|
|
|a breast cancer risk
|
653 |
|
|
|a ethanol
|
653 |
|
|
|a acute myeloid leukemia
|
653 |
|
|
|a innate immunity
|
653 |
|
|
|a polyphenols
|
653 |
|
|
|a gliomas
|
653 |
|
|
|a phytochemicals
|
653 |
|
|
|a Malva pseudolavatera Webb &
|
653 |
|
|
|a resistance
|
653 |
|
|
|a berberine
|
653 |
|
|
|a daidzein metabolites
|
653 |
|
|
|a preclinical models
|
653 |
|
|
|a HO-1
|
653 |
|
|
|a non-coding RNAs
|
653 |
|
|
|a angiogenesis
|
653 |
|
|
|a natural compounds
|
653 |
|
|
|a inflammation
|
653 |
|
|
|a breast cancer prognostic
|
653 |
|
|
|a n/a
|
653 |
|
|
|a brain cancer
|
653 |
|
|
|a human cancer cells
|
653 |
|
|
|a drugs
|
653 |
|
|
|a gemcitabine
|
653 |
|
|
|a pancreatic cancer
|
653 |
|
|
|a epithelial mesenchymal transition
|
653 |
|
|
|a cancer stem cell
|
653 |
|
|
|a anticancer drugs
|
653 |
|
|
|a ER stress
|
653 |
|
|
|a AMPK
|
653 |
|
|
|a nicotine
|
653 |
|
|
|a small organic agents
|
653 |
|
|
|a ROS
|
653 |
|
|
|a colon cancer cells
|
653 |
|
|
|a Nrf2
|
653 |
|
|
|a microRNAs
|
653 |
|
|
|a malignant tumors of the peripheral nerve sheath (MPNST)
|
653 |
|
|
|a estrogen receptor alpha
|
653 |
|
|
|a anti-cancer drug
|
653 |
|
|
|a AOM/DSS model
|
653 |
|
|
|a anticancer
|
653 |
|
|
|a STAT3
|
653 |
|
|
|a PD-L1
|
653 |
|
|
|a eicosapentaenoic acid
|
653 |
|
|
|a bioactivities
|
653 |
|
|
|a chemoprevention
|
653 |
|
|
|a glucose transport
|
653 |
|
|
|a apoptosis
|
653 |
|
|
|a RacGAP1
|
653 |
|
|
|a glycolytic markers
|
653 |
|
|
|a breast cancer
|
653 |
|
|
|a gigantol
|
653 |
|
|
|a multiple myeloma
|
653 |
|
|
|a experimental therapeutics
|
653 |
|
|
|a signalling pathway
|
653 |
|
|
|a mesoporous silica nanoparticles
|
653 |
|
|
|a pro-resolving lipids
|
653 |
|
|
|a Calocedrus formosana
|
653 |
|
|
|a FASN inhibitors
|
653 |
|
|
|a isorhamnetin
|
653 |
|
|
|a uterine sarcoma
|
653 |
|
|
|a glycolysis
|
653 |
|
|
|a paclitaxel
|
653 |
|
|
|a obesity
|
653 |
|
|
|a yatein
|
653 |
|
|
|a formononetin
|
653 |
|
|
|a proteomics
|
653 |
|
|
|a cancer therapy
|
653 |
|
|
|a melanoma cells
|
653 |
|
|
|a metastasis
|
653 |
|
|
|a anticancer drug
|
653 |
|
|
|a estrogen
|
653 |
|
|
|a natural anti-inflammatory compounds
|
653 |
|
|
|a mangrove
|
653 |
|
|
|a HDAC
|
653 |
|
|
|a Streptomyces
|
653 |
|
|
|a nanoparticle-based delivery systems
|
653 |
|
|
|a G2/M arrest
|
653 |
|
|
|a Berthel.
|
653 |
|
|
|a honokiol
|
653 |
|
|
|a α9-nAChR
|
653 |
|
|
|a colchicine alkaloid
|
653 |
|
|
|a flavonoids
|
653 |
|
|
|a xenograft
|
653 |
|
|
|a breast cancer cells
|
653 |
|
|
|a tumor density
|
653 |
|
|
|a bioavailability
|
653 |
|
|
|a malignant cancer
|
653 |
|
|
|a nobiletin
|
700 |
1 |
|
|a Luparello, Claudio
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
028 |
5 |
0 |
|a 10.3390/books978-3-03943-293-6
|
856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/2970
|7 0
|x Verlag
|3 Volltext
|
856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/69198
|z DOAB: description of the publication
|
082 |
0 |
|
|a 000
|
082 |
0 |
|
|a 140
|
082 |
0 |
|
|a 380
|
082 |
0 |
|
|a 700
|
520 |
|
|
|a Recent years have seen the idea of a close association between nutrition and the modulation of cancer development/progression reinforced. An increasing amount of experimental and epidemiological evidence has been produced supporting the concept that many different bioactive components of food (e.g. polyphenols, mono- and polyunsaturated fatty acids, methyl-group donors, etc.) may be implicated in either the promotion of or the protection against carcinogenesis. At the cellular level, such compounds can have an impact on different but sometimes intertwined processes, such as growth and differentiation, DNA repair, programmed cell death, and oxidative stress. In addition, compelling evidence is starting to build up of the existence of primary epigenetic targets of dietary compounds, such as oncogenic/oncosuppressor miRNAs or DNA-modifying enzymes, which in turn impair gene expression and function. Since there is a growing interest in the study of the biochemical and molecular role played by food components and its impact on cellular processes and/or gene expressions directed towards the fine-tuning of cancer phenotypes, in this Special Issue researchers contributed with either research or review articles presenting the latest findings on the intracellular pathways and mechanisms affected by natural bioactive dietary molecules.
|